Citations

Clear

3138 citation(s) found for "Smith, AM".

Endocrine and Metabolic Diseases Among Colorectal Cancer Survivors in a Population-Based Cohort
Hawkins, Makenzie, Blackburn, Brenna E. , Rowe, Kerry , Snyder, John , Deshmukh, Vikrant , Newman, Michael , Fraser, Alison , Smith, Ken R. , Herget, Kimberly A. , Ganz, Patricia A. , Samadder, N. Jewel , Hashibe, Mia, Snyder, John

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 26, 2019 | Volume: 112 | Issue: 1 | Pages: 78-86

10.1093/jnci/djz040 | PMID 30918958 Get It

Abstract Background There are an estimated 1.4 million colorectal cancer (CRC) survivors in the United States. Research on endocrine and metabolic diseases over the long term in CRC survivors is limited. Obesity is a risk factor for CRC; thus it is of interest to investigate diseases that may share this risk factor, such as diabetes, for long-term health outcomes among CRC survivors. Methods A total of 7114 CRC patients were identified from the Utah Population Database and matched to a general population cohort of 25 979 individuals on birth year, sex, and birth state. Disease diagnoses (assessed over three time periods of 1–5 years, 5–10 years, and >10 years) were identified using electronic medical records and statewide ambulatory and inpatient discharge data. Cox proportional hazard models were used to estimate the risk of endocrine and metabolic disease. Results Across all three time periods, risks for endocrine and metabolic diseases were statistically significantly greater for CRC survivors compared with the general population cohort. At 1–5 years postdiagnosis, CRC survivors’ risk for diabetes mellitus with complications was statistically significantly elevated (hazard ratio [HR] = 1.36, 99% confidence interval [CI] = 1.09 to 1.70). CRC survivors also experienced a 40% increased risk of obesity at 1–5 years postcancer diagnosis (HR= 1.40, 99% CI= 1.66 to 2.18) and a 50% increased risk at 5–10 years postdiagnosis (HR = 1.50, 99% CI= 1.16 to 1.95). Conclusions Endocrine and metabolic diseases were statistically significantly higher in CRC survivors throughout the follow-up periods of 1–5 years, 5–10 years, and more than 10 years postdiagnosis. As the number of CRC survivors increases, understanding the long-term trajectory is critical for improved survivorship care.
PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas
Caudle, Kelly E. , Gammal, Roseann S., Karnes, Jason H. , Afanasjeva, Janna, Anderson, Keri C. , Frazee, Erin N. , Beavers, C. , Bhat, Shubha , Birrer, Kara L., Ensor, Christopher R. , Flowers, Stephanie A. , Formea, Christine M. , George, Jomy, Gosser, Rena , Karaoui, Lamis R. , Kolpek, Jimmi Hatton , Leung, Jonathan G. , Maldonado, Angela Q. , Minze, Molly G. , Pulk, Rebecca , Shelton, Chasity M. , Sheridan, Maria , Smith, Michael A. , Soefje, Scott A. , Tellez‐Corrales, Eglis , Walko, Christine M. , Leung, Jonathan G , Soefje, Scott A , Chahine, Elias B. , Hébert, Mary F. , Lee, James C. , Sheridan, Maria, Cavallari, Larisa H.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 25, 2019 | Volume: 2 | Issue: 3 | Pages: 288-302

10.1002/jac5.1107 Get It

Clinical pharmacists have been incorporating precision medicine into practice for decades. Drug selection and dosing based on patient‐specific clinical factors such as age, weight, renal function, drug interactions, plasma drug concentrations, and diet are expected as part of routine clinical practice. Newer concepts of precision medicine such as pharmacogenomics have recently been implemented into clinical care, while other concepts such as epigenetics and pharmacomicrobiomics still predominantly exist in the research area but clinical translation is expected in the future. The purpose of this paper is to describe current and emerging aspects of precision medicine as it relates to clinical pharmacy across a variety of specialty areas of practice, with perspectives from the American College of Clinical Pharmacy Practice and Research Network membership.
Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter‐Defibrillator Therapies
Hajduk, Alexandra M. , Gurwitz, Jerry H. , Tabada, Grace H., Masoudi, Frederick A. , Magid, David J. , Greenlee, Robert T. , Sung, Sue Hee, Liu, Taylor I. , Smith, David H. , Fiocchi, Frances, Gill, Thomas M. , Gupta, Nigel, Peterson, Pamela N., Schuger, Claudio , Vidaillet, Humberto, Hammill, Stephen C., Allore, Heather , Go, Alan S. , Gill, Thomas M , Cassidy‐Bushrow, Andrea E. , Liu, Taylor , Reynolds, Kristi , Goldberg, Robert Joel , Peterson, Pamela N.

Mayo Clinic

Journal of the American Geriatrics Society | March 20, 2019 | Volume: 67 | Issue: 7 | Pages: 1370-1378

10.1111/jgs.15839 | PMID 30892695 Get It

OBJECTIVE To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies. DESIGN Retrospective cohort study. SETTING Seven US healthcare delivery systems. PARTICIPANTS Adults with left ventricular systolic dysfunction receiving an implantable cardioverter‐defibrillator (ICD) for primary prevention. MEASUREMENTS Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0‐3, 4‐5, 6‐7 and 8‐16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy. RESULTS Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4‐8), with 98% having at least two comorbidities. During a mean 2.2 years of follow‐up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14‐3.31] for 4‐5 comorbidities; HR = 2.25 [95% CI = 1.25‐4.05] for 6‐7 comorbidities; and HR = 2.91 [95% CI = 1.54‐5.50] for 8‐16 comorbidities). Participants with 8‐16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43‐3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67‐6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07‐2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies. CONCLUSIONS In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation.
Response: Goniotomy Using the Kahook Dual Blade in Severe and Refractory Glaucoma: 6-Month Outcomes
Salinas, Lauriane, Chaudhary, Ankita, Lazcano-Gómez, Gabriel , Williamson, Blake K. , Dorairaj, Syril , Seibold, Leonard K., Smith, Sanjay, Aref, Ahmad A. , Darlington, Jason K., Jiménez-Román, Jesús, Mahootchi, Ahad , Boucékine, Mohamed , Mansouri, Kaweh , Dorairaj, Syril K., Berdahl, John Palmer

Mayo Clinic

Journal of Glaucoma | March 19, 2019 | Volume: 28 | Issue: 5 | Pages: e89-e89

10.1097/ijg.0000000000001211 | PMID 31048641 Get It

Self-Efficacy Mediates the Association Between Physical Function and Perceived Quality of Life in Individuals with Mild Cognitive Impairment
Langer, Kailey , O’Shea, Deirdre , Wit, Liselotte De , DeFeis, Brittany , Mejia, Andrea, Amofa, Priscilla , Chandler, Melanie , Fields, Julie A. , Phatak, Vaishali , Dean, P.M. , Locke, Dona E.C. , De Wit, Liselotte , Mejia, Andrea, Dean, Pamela M., Smith, Glenn E.

Mayo Clinic

Journal of Alzheimer’s Disease | March 19, 2019 | Volume: 68 | Issue: 4 | Pages: 1511-1519

10.3233/jad-181020 | PMID 30909227 Get It

Background: Research has shown that individuals with mild cognitive impairment (MCI) value quality of life (QoL) above and beyond cognitive function or other potential outcomes in MCI. There is evidence supporting the negative impact of poor physical function on QoL ratings. Objective: The study explored whether a modified measure of self-efficacy for managing MCI and education mediated and/or moderated the relationship between physical function and QoL in persons with MCI. Methods: Baseline data from 200 participants with MCI were obtained from a larger study assessing the effectiveness of a behavioral intervention. Physical function was assessed by the Short Physical Performance Battery. QoL was assessed with the Quality of Life in Alzheimer’s Disease scale. Memory-related self-efficacy was assessed using a modified 9-item version of the Chronic Disease Self-Efficacy Scales. Mediation and moderation analyses tested the hypotheses that self-efficacy and education alter the association between physical function and QoL in individuals with MCI. All analyses were adjusted for age, cognitive severity, and sex. Results: Self-efficacy for managing MCI was a significant mediator of the association between physical function and perceived QoL. Individuals with better physical function reported higher self-efficacy which was associated with higher QoL ratings. Conclusions: Greater self-efficacy for managing MCI mediated the negative association between physical function and quality of life in this exploratory study. Interventions aimed at enhancing memory self-efficacy in MCI may improve perceived QoL, even in the presence of poor physical function. Future research is needed to investigate this further.
Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival
Baraghoshi, David , Garrido‐Laguna, Ignacio , Gilcrease, Glynn Weldon, Whisenant, Jonathan, Weis, John R., Scaife, Courtney L. , Pickron, T. Bartley, Huang, Lyen C. , Monroe, Marcus M. , Abdelaziz, Sarah, Fraser, Alison , Deshmukh, Vikrant , Rowe, Kerry , Snyder, John , Samadder, N. Jewel , Hashibe, Mia, Samadder, Niloy J, Lloyd, Shane , Tao, Randa , Smith, Ken R. , Newman, Michael , Snyder, John

Mayo Clinic

American Journal of Clinical Oncology | March 18, 2019 | Volume: 42 | Issue: 4 | Pages: 355-362

10.1097/coc.0000000000000529 | PMID 30844850 Get It

Objectives: To determine the risk and risk factors for mental illness among colorectal cancer (CRC) survivors across short-term and long-term follow-up periods. Methods: We used the Utah Cancer Registry to identify CRC survivors diagnosed between 1997 and 2013. Mental health diagnoses were available in electronic medical records and statewide facilities data that were linked by the Utah Population Database. CRC survivors were matched to individuals from a general population cohort. The risk of developing a mental illness was compared between cohorts. The association between mental illness and mortality was also analyzed. Results: In total, 8961 CRC survivors and 35,897 individuals in a general population cohort were identified. CRC survivors were at increased risk for any mental health diagnosis at 0 to 2 years (hazard ratio [HR], 3.70; 95% confidence interval [CI], 3.47-3.95), >2 to 5 years (HR, 1.23; 95% CI, 1.09-1.38), and >5 years (HR, 1.20; 95% CI, 1.07-1.36) after cancer diagnosis. CRC survivors were also at increased risk of depressive disorders specifically during the same time periods. At >5 years, CRC survivors still had an increased risk of developing many mental health diagnoses. Factors associated with increased risk of any mental health disorder among CRC survivors included colostomy and Charlson Comorbidity Index of 1+. There was an increased risk of death for CRC survivors diagnosed with any mental health disorder (HR, 2.18; 95% CI, 2.02-2.35) and depression (HR, 2.10; 95% CI, 1.92-2.28). Conclusions: CRC survivors are at increased risk for mental health disorders in the short-term and long-term. Survivors who develop mental health disorders also experience decreased survival.
Faculty Opinions recommendation of Guidelines for the use of flow cytometry and cell sorting in immunological studies.
Lehrke, Michael Jonathan , Shapiro, Virginia Smith

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.731982221.793557362 Get It

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Gelman, Rebecca , Anders, Carey K. , Melisko, Michelle , Parsons, Heather A. , Cropp, Anne B., Silvestri, Kelly M., Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Connolly, Roisín M. , Poznak, Catherine Van , Blackwell, Kimberly , Puhalla, Shannon L. , Jankowitz, Rachel C. , Ibrahim, Nuhad K. , Moynihan, Timothy J. , O’Sullivan, Ciara C. , Nangia, Julie R. , Pohlmann, Paula R. , Burns, Robyn, Rimawi, Mothaffar F. , Krop, Ian E. , O'Sullivan, Ciara C, Rimawi, Mothaffar , Freedman, Rachel A. , Moy, Beverly , Smith, Karen L. , Niravath, Polly Ann , Tung, Nadine , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U. , Pohlmann, Paula

Mayo Clinic

Journal of Clinical Oncology | March 12, 2019 | Volume: 37 | Issue: 13 | Pages: 1081-1089

10.1200/jco.18.01511 | PMID 30860945 Get It

PURPOSE Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from additional study cohorts. PATIENTS AND METHODS Patients with measurable, progressive, HER2-positive brain metastases (92% after receiving CNS surgery and/or radiotherapy) received neratinib 240 mg orally once per day plus capecitabine 750 mg/m 2 twice per day for 14 days, then 7 days off. Lapatinib-naïve (cohort 3A) and lapatinib-treated (cohort 3B) patients were enrolled. If nine or more of 35 (cohort 3A) or three or more of 25 (cohort 3B) had CNS objective response rates (ORR), the drug combination would be deemed promising. The primary end point was composite CNS ORR in each cohort separately, requiring a reduction of 50% or more in the sum of target CNS lesion volumes without progression of nontarget lesions, new lesions, escalating steroids, progressive neurologic signs or symptoms, or non-CNS progression. RESULTS Forty-nine patients enrolled in cohorts 3A (n = 37) and 3B (n = 12; cohort closed for slow accrual). In cohort 3A, the composite CNS ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohort 3B = 33% (95% CI, 10% to 65%). Median progression-free survival was 5.5 and 3.1 months in cohorts 3A and 3B, respectively; median survival was 13.3 and 15.1 months. Diarrhea was the most common grade 3 toxicity (29% in cohorts 3A and 3B). Neratinib plus capecitabine is active against refractory, HER2-positive breast cancer brain metastases, adding additional evidence that the efficacy of HER2-directed therapy in the brain is enhanced by chemotherapy. For optimal tolerance, efforts to minimize diarrhea are warranted.
Identifying predictive biomarkers for metastatic progression in stage I and II clear cell renal cell carcinoma.
Murphy, Neal , Shih, Andrew , Kozel, Zachary , Shah, Paras , Yaskiv, Oksana, Khalili, Houman , Liew, Anthony, Kavoussi, Louis R., Hall, Simon J. , Vira, Manish , Lee, Annette , Zhu, Xinhua , Khalili, Houman

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 631-631

10.1200/jco.2019.37.7_suppl.631 Get It

631 Background: For most clear cell renal cell carcinoma (ccRCC) patients with early stage disease, surgical resection offers definitive cure. However, for the small percentage of tumors that metastasize, analyzing gene expression profiles from the primary site at the time of nephrectomy can serve as a model to understand the molecular aberrations behind a metastatic phenotype. Differences in gene expression profiles between patients with Stage I and II ccRCC who experience metastasis versus patients who maintain cure after surgery may help elucidate significant molecular targets and stratify patients at higher risk for metastasis. Methods: Nineteen Stage I and twenty Stage II ccRCC tumors preserved in FFPE blocks after nephrectomy were included in this study. Patients were matched for age, gender, tumor size and grade. In both stages, approximately half the patients that experienced metastasis within 5 years of surgery were part of the experimental group, whereas the control group had > 5 years of follow-up without evidence of disease. Extracted RNA for Stage I patients was sequenced using Illumina TruSeq RNA Access Library. Gene counts were assessed by ht-seq counts and differential expression using DESeq2. Significant genes found were validated in the Stage II group using RT-qPCR. Results: In the Stage I experimental group, statistically significant upregulation of several genes associated with unfavorable prognosis in RCC were found: COL1A1, NUMBL, and STEAP3. Random forest classification accurately separated Stage I control versus experimental patients based on expression of COL1A1. Affected genes were consistent with molecular changes seen in TCGA analysis. In the Stage II group, a double-blinded analysis correctly identified the clinical outcome for the majority of the patients using qPCR expression of COL1A1, NUMBL, and STEAP3. Conclusions: Differences in gene expression profiles harbored in the primary site of early stage ccRCC may be employed to predict patients at high risk for developing metastasis. Validating these findings in a larger study carries the potential to better understand mechanisms of metastasis and identify an at risk cohort of patients with early stage disease.
Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.
Pitot, Henry C., Hurwitz, Herbert I. , Zanna, Claudio , Brill, Jeffrey Mark, Vuagniaux, Grégoire, Rouits, Elisabeth , Sorensen, John M., Smith, David C.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2531-2531

10.1200/jco.2015.33.15_suppl.2531 Get It